- ã¿ã¤ãã«ï¼ICD-11åºæºã«åºã¥ããã²ã¼ã é害ããã³æ害ã²ã¼ã ã®ç²¾ç¥é害ã¨é¢é£å åã«é¢ããçä¾å¯¾ç §ç 究ï¼èªç¥çå¶å¾¡ãæ å調æ´ãããã³å¼·åæåæ§ã
- ã¿ã¤ãã«ï¼åã©ããææ¥æã®é£äºã¨ç¹å¥æ¯æ´æè²ãã¼ãºï¼SENsï¼ï¼ç³»çµ±çã¬ãã¥ã¼
- Therapeutic drug monitoring vs. pharmacogenetic testing in the
- ã¿ã¤ãã«ï¼ã¡ã³ã¿ã«é害æ£è ã®ã¢ã¦ãã«ã ã«å¯¾ããL-ãã¢ãã³è£çµ¦ã®å¹æï¼ä½ç³»çã¬ãã¥ã¼
- Title: ãã¦ã¹ã«ãããå帯ç¶ç®è³ªã¸ã®å¯è ç®è³ªæºã®åºæ¿ã¯ãApoeéºä¼åã®ç´°èåç¹ç°ççºç¾ãèªå°ããã
- Differences in impulsivity between adolescents with ADHD and those
- ã¿ã¤ãã«ï¼æ³¨ææ¬ é¥å¤åæ§é害ï¼ADHDï¼ã«ãããè³è¡æµï¼ã·ã¹ãããã£ãã¯ã¬ãã¥ã¼
- ã¿ã¤ãã«ï¼ã¤ã³ããã·ã¢ã«ããã注ææ¬ é¥å¤åæ§é害ï¼ADHDï¼ãæã¤åä¾ã®çè·ãã¿ã¼ã³ã«è¦ªã®æè²ãä¸ããå½±é¿
- ã¿ã¤ãã«ï¼ãã¥ã¼ãã³ã¢ã¯ã·ã§ã³ããã»ã¹ãã¬ã¼ã ã¯ã¼ã¯ãç¨ãã¦ã注ææ¬ é¥å¤åæ§é害ã®åä¾ã®ä»è·è ã«ãããè¡å決å®è¦å ã調æ»ããã
- ã¿ã¤ãã«: è¥è ã®ä¸æ³¨æ/å¤åæ§ã¨ã½ã¼ã·ã£ã«ã¡ãã£ã¢ä¾åã®é¢é£ï¼èªå·±è²¬ãã¨ä»è 責ãã«ãããææ 調ç¯æ¦ç¥ã®ä¸ä»å¹æ
ã¿ã¤ãã«ï¼ICD-11åºæºã«åºã¥ããã²ã¼ã é害ããã³æ害ã²ã¼ã ã®ç²¾ç¥é害ã¨é¢é£å åã«é¢ããçä¾å¯¾ç §ç 究ï¼èªç¥çå¶å¾¡ãæ å調æ´ãããã³å¼·åæåæ§ã
è¦ç´ï¼
- ç¾å¨ã®ç 究ã®ç®çã¯ãDSM-5åºæºã«åºã¥ãã¤ã³ã¿ã¼ãããã²ã¼ã é害ï¼IGDï¼ã®å è¡å ±åãããç²¾ç¥é害ããICD-11åºæºã«åºã¥ãã²ã¼ã é害ï¼GDï¼ã¾ãã¯æ害ã²ã¼ã ï¼HGï¼ã®æ¹ãããä¸è¬çã§ãããã©ãããç¥ããã¨ã§ãã£ãã
- GDã¨HGã«é¢é£ããç²¾ç¥é害ããã³é¢é£å åãè©ä¾¡ããããã«ã60人ã®GDã45人ã®HGãããã³120人ã®ã³ã³ããã¼ã«ãICD-11åºæºã«åºã¥ãã診æã¤ã³ã¿ãã¥ã¼ã§è©ä¾¡ããã
- GDã¯ADHDããã¤ç ãããã³GADã¨é¢é£ãã¦ãããHGã¯ADHDã¨æãé¢é£ããã£ãããã¤ç ã¯HGã«æ¯ã¹ã¦GDã¨é¢é£ãã¦ãããã¾ããGDã®è¨ºæãåããããã®ã¯ãåè©ä¾¡ãä½ããå«æªæåæ§ãé«ããè¡åæ§ãé«ãå人ã§ãã£ããä¸æ¹ãHGã®è¨ºæãåããããã®ã¯ã楽ãã¿ãæ±ãã人ã§ãã£ãã
- ç¾å¨ã®ç 究ã§ã¯ãGDã«æãææã«é¢é£ããç²¾ç¥é害ã¯ADHDã§ããããã®æ¬¡ã«ãã¤ç ã¨GADããã£ããADHDã¯ã¾ãHGã¨é¢é£ãã¦ããããã¤ç ã¯GDã¨æ¯è¼ãã¦HGã¨ããé¢é£ãã¦ãããHGããã³GDã¸ã®ä»å ¥ã¯ãã¯ã©ã¤ã¢ã³ãã®ç²¾ç¥é害ã ãã§ãªãåè©ä¾¡ã¹ãã«ãè¡åæ§ãå«æªæåæ§ãããã³æ¥½ãã¿ãæ±ããå¾åãèæ ®ãã¦ã«ã¹ã¿ãã¤ãºãããã¹ãã§ããã
ã¿ã¤ãã«ï¼åã©ããææ¥æã®é£äºã¨ç¹å¥æ¯æ´æè²ãã¼ãºï¼SENsï¼ï¼ç³»çµ±çã¬ãã¥ã¼
è¦ç´ï¼
- ç¹å¥æ¯æ´æè²ãã¼ãºï¼SENsï¼ã¯ã追å ã®æè²æ¯æ´ãå¿ è¦ã¨ããåã©ããææ¥æã®ãã¨ãæãã
- å¦å¨ ä¸ãå°å æã®é£äºã¯ãSENé¢é£ã®ç¶æ ãé害ã®æç ç/éç度ã«å½±é¿ãä¸ããå¯è½æ§ãããã
- ãã®ã¬ãã¥ã¼ã¯ãï¼iï¼å¦å¨ ä¸ã®å¥³æ§ã®é£äºã¨åã©ã/ææ¥æã®SENé¢é£ã®ç¶æ /é害ã®æç çã¨ï¼iiï¼SENé¢é£ã®ç¶æ /é害ãæã¤åã©ã/ææ¥æã®é£äºã¨ãã®çç¶/幸ç¦æã¨ã®é¢é£ãã¾ã¨ãããã¨ãç®çã¨ãã¦ããã
- Medlineã¨Scopusã§æç®æ¤ç´¢ãè¡ããPRISMAã¬ã¤ãã©ã¤ã³ã«å¾ã£ãã87ã®è¨äºãå«ã¾ãã41ã®è¨äºãADHDã34ã®è¨äºãASDã«è¨åãã¦ããã
- 注ç®ãã¹ãçµæã¯ãæ¯è¦ªã®ã«ãã§ã¤ã³æåãå¦å©¦ã®ãã«ããã¿ãã³è£å ãåã©ã/ææ¥æã®é«ç³åé£åã飲ææåãæ¯è¦ªã®æ¯ä¹³è²å ããã¿ãã³Dè£å ã«é¢ããã
- é¡èãªé¢ä¿ãè¦ããããããããã®çµæãå¼·åããããã«ããæ¨æºåãããæ¹æ³è«ãå¿ è¦ã§ãããPROSPEROç»é²çªå·ï¼CRD42022313235ã
Therapeutic drug monitoring vs. pharmacogenetic testing in the
context of elevated olanzapine concentrations and prior clozapine
intolerability: a case study.
- èæ¯
- ãªã©ã³ã¶ãã³ã¨ã¯ãã¶ãã³ã«å¯¾ããæ²»çè¬ã¢ãã¿ãªã³ã°ã®å¼·åãªè¨¼æ ãåå¨ããã
- ãã ãããªã©ã³ã¶ãã³ã®æ²»çè¬ã¢ãã¿ãªã³ã°ã¯ãã°ãã°æ´»ç¨ããã¦ããªãã
- æç²¾ç¥ç
è¬ã®éºä¼ååã«åºã¥ãæä¸ã«é¢ãã証æ ã¯ãç¹ã«CYP1A2代è¬è¬ï¼ãªã©ã³ã¶ãã³ããã³ã¯ãã¶ãã³ãªã©ï¼ã«ã¤ãã¦ã¯ããã»ã©ããã¹ãã§ã¯ãªãã
- çä¾çºè¡¨
- çµ±å失調æ§é害-å極æ§ã¿ã¤ããADHDãããã³èªéã¹ãã¯ãã©ã é害ãæã¤32æ³ã®ç½äººç·æ§ããæç²¾ç¥ç
è¬ã®å¤å¤æä¸ã«ããéä½å¤è·¯çç¶ãåãã転åãç¹°ãè¿ãã
- ãªã©ã³ã¶ãã³40 mgã§é¨ååå¿ãçµé¨ãããã®å¾50 mgã«å¢éããããããªã©ã³ã¶ãã³ã®ãã©ãã§ã¯152 ng/mLã®è¶
æ²»çéãæ¤åºãããã
- ã¨ãã½ã¼ãæ§éº»çºçç¶ã®æ¢å¾æ´ãã¯ãã¶ãã³ã«ããä»ã®å ±åãããæ害åå¿ãèæ
®ããæ£è
ã¯ã¯ãã¶ãã³ã«å¾ã
ã«ã¯ãã¹ãã¼ãã¼ãããªã©ã³ã¶ãã³ã¬ãã«ãé«ããªãã¨èããããã
- ã¯ãã¶ãã³ã¯å¹æçã§ããè容ãããããæ£è
ã¯äºæ³éããå¹´é½¢ãæ°ææ§ãããã³æ§å¥ã«æ¯ãã¦ã¯ãã¶ãã³ãã©ãæ¿åº¦ãé«ãã£ãã
- çµè«
- æ¬çä¾ã¯ãCYP1A2代è¬ã®å¤ç°ãçãããæ£è
ã«å¯¾ãã¦ã¯ãè¬ç©ã¢ãã¿ãªã³ã°ãè¬çéºä¼å¦æ¤æ»ãããæç¨ã§ãããã¨ã示ãã¦ããã
- ç¹ã«ãCYP1A2æ´»æ§ãä½ä¸ãã¦ããã¨çãããå ´åã«ã¯ãæ¨æºçãªåç¨è¬çéºä¼å¦ããã«ã§ç°¡åã«æ¤åºã§ããªãé
µç´ æ©è½ä½ä¸ãå¼ãèµ·ãããµãã¢ã¬ã«ãããã±ã¼ã¹ã§ã¯ãæ²»çè¬ã¢ãã¿ãªã³ã°ãããå®ç¨çãªã¢ããã¼ãã¨ãã¦æµ®ãã³ä¸ãã£ã¦ããã
ã¿ã¤ãã«ï¼ã¡ã³ã¿ã«é害æ£è ã®ã¢ã¦ãã«ã ã«å¯¾ããL-ãã¢ãã³è£çµ¦ã®å¹æï¼ä½ç³»çã¬ãã¥ã¼
è¦ç´ï¼
- èæ¯ï¼
- æãã¤è¬ãæç²¾ç¥æ§è¬ãããã³ä»ã®ç²¾ç¥è¬çè¬å¤ã¨ã®è£å©ã¨ãã¦ä½¿ç¨ãããéãL-ãã¢ãã³ï¼LTï¼ãªã©ã®ç¹å®ã®ã¢ããé
¸ã¯ãã¡ã³ã¿ã«é害æ£è
ã®çç¶ä¸ã®çµæãåä¸ãããå¯è½æ§ã示ããã¦ãã¾ãã
- ããã«ããããããããããã®é¢é£ãæ¤è¨ãã以åã®ä½ç³»çã¬ãã¥ã¼ãæ¬ å¦ãã¦ãã¾ãããã®ãããLTè£çµ¦ãç²¾ç¥ä¿å¥é害æ£è
ã®çµæã«ä¸ããå½±é¿ã調æ»ããç¡ä½çºå対ç
§è©¦é¨ã®ä½ç³»çã¬ãã¥ã¼ãå®æ½ãã¾ããã
- æ¹æ³ï¼
- è¨åºçãªä½ç³»çã¬ãã¥ã¼ãå®æ½ãããã®ä¸ã§ãLTè£çµ¦ãç²¾ç¥ä¿å¥é害æ£è
ã®çµæã«ä¸ããå½±é¿ã調æ»ããç¡ä½çºå対ç
§è©¦é¨ã«ç¹åãã6ã¤ã®é»åãã¼ã¿ãã¼ã¹ï¼PubMedãScopusãPsycINFOãWeb
of ScienceãCINAHL CompleteãCochraneï¼ã調æ»ãã¾ããã
- å«ã¾ããç 究ã®è³ªãè©ä¾¡ããããã«ãCochraneã®ç¡ä½çºå試é¨ã®åããªã¹ã¯ãã¼ã«ã使ç¨ããã¾ããã
- çµæï¼
- 419ã®åºçç©ã®ãã¡ãã¤ã¹ã©ã¨ã«ãã¤ã©ã³ãã¢ã¡ãªã«ãæ¥æ¬ããªã¼ã¹ãã©ãªã¢ãã¤ã¿ãªã¢ã®11ã®ç 究ãæçµåæã«å«ã¾ãã¾ããã
- ãããã®ç 究ã¯ãçµ±å失調çã注ææ¬ é¥/å¤åæ§é害ï¼ADHDï¼ãå¼·è¿«æ§é害ï¼OCDï¼ã大ãã¤ç
ãç¡ç é害ãåºæ±æ§ä¸å®é害ï¼GADï¼ããã¥ã¬ããçå群ãªã©ã®å¹
åºãã¡ã³ã¿ã«é害ãã«ãã¼ãã¦ãã¾ããã
- 調æ»çµæã¯ãLTè£çµ¦ãçµ±å失調çãä¸å®é害ãããã³ADHDãæã¤å人ã®ç²¾ç¥çç¶ããã³ã³ããã¼ã«æ¡ä»¶ãããå¹æçã«æ¸å°ããããã¨ã示ãã¾ããã
- çµè«ï¼
- ãã®ä½ç³»çã¬ãã¥ã¼ã®çµæã¯ãLTè£çµ¦ãçµ±å失調çãä¸å®é害ãããã³ADHDãæã¤å人ã®ç²¾ç¥çç¶ããã³ã³ããã¼ã«æ¡ä»¶ãããå¹æçã«æ¸å°ããããã¨ã示ãã¦ãã¾ãã
- ãããããããã®çµæãæ¤è¨¼ãã観å¯ãããå¹æã®ç解ãæ·±ãããããã®é¢é£æ§ã®ã¡ã«ããºã ãæ¢ãããã«ããããªãç 究ãå¿
è¦ã§ãã
Title: ãã¦ã¹ã«ãããå帯ç¶ç®è³ªã¸ã®å¯è ç®è³ªæºã®åºæ¿ã¯ãApoeéºä¼åã®ç´°èåç¹ç°ççºç¾ãèªå°ããã
- å帯ç¶ç®è³ªï¼mFCï¼ã¨å¯è ç®è³ªï¼LCï¼ã¯ã注æãè¨æ¶ãææ決å®ãªã©ã®èªç¥ç¾è±¡ã«é¢ä¸ãã¦ããããããã®è³é åã®ååã¬ãã«ã§ã®èª¿ç¯å åã¯ããç解ããã¦ããªããããããã®èªç¥é åã«é害ãåããç¾æ£ã®åºç¤çã¡ã«ããºã ãæããã«ããã®ã«å½¹ç«ã¤å¯è½æ§ãããã
- LCã®ãã¥ã¼ãã³ãåºæ¿ããmFCã®PrLã«ä»çããææ¡ä½åé ç®è³ªãã¥ã¼ãã³ã«æå°ãããRNAsãç¨ãã¦ããã¦ã¹PrLããã®å ¨RNAã·ã¼ã±ã³ã·ã³ã°ãè¡ã£ãããã®åè·¯ã®åºæ¿ã¯ãApoeéºä¼åãå«ãä¸é£ã®éºä¼åã®è»¢åå¢å ãå¼ãèµ·ããããPrLã«ãããApoeã®ç´°èåç¹ç°ççºç¾ã®èª¿æ»ã§ã¯ãLCããPrLã«ããã¸ã§ã¯ã·ã§ã³ãããã¥ã¼ãã³ã«åºæ¿çãªDREADDå容ä½hM3Dqãçºç¾ããããã¥ã¢ã«ã¦ã¤ã«ã¹ã¢ããã¼ãã使ç¨ããLCå ¥åã®è±å極å¾ã®PrLã«ãããApoeçºç¾ã®å¢å ã¯ãGABAä½åæ§ãã¥ã¼ãã³ã§æ§ä¾åçã«è±ãã§ãããã¨ã示ãããã
- ãããã®å®é¨ã®çµæã¯ãApoeçºç¾ãã注æãè¨æ¶ãææ決å®ã«éè¦ãªç®è³ªå¾®ç´°åè·¯ã«ãããæ©è½ã«ã©ã®ããã«å½±é¿ãããã«ã¤ãã¦æ´å¯ãæä¾ãã注ææ¬ é¥å¤åæ§é害ï¼ADHDï¼ãçµ±å失調çãã¢ã«ããã¤ãã¼ç ï¼ADï¼ãªã©ã®é害ã«ãããåè·¯æ©è½ã®ãã¤ãªãã¼ã«ã¼ã¨ãã¦ã®Apoeã®å å æ§é¸æççºç¾ãææãã¦ããã
Differences in impulsivity between adolescents with ADHD and those
with comorbidity of ADHD and IGD.
- ADHDæ£è ã¯é«ãè¡åæ§ã示ããã¨ãå¤ã
- ADHDã¨ã¤ã³ã¿ã¼ãããã²ã¼ã é害ï¼IGDï¼ã®åä½µçãæã¤æ£è ã¨åç¬ã®ADHDãæã¤æ£è ã¨ã®éã®è¡åæ§ã®éãã«ã¤ãã¦ã®ç 究ã¯ã»ã¨ãã©ãªã
- 81人ã®åç¬ã®ADHDãæã¤10代ã®è¥è ã¨ãADHDã¨IGDã®åä½µçãæã¤59人ã®æ£è ãå«ã¾ããå®é¨ãè¡ãããStop-signal
Taskï¼SSTï¼ãDelay Discount Taskï¼DDTï¼ãBalloon Analogue Risk
Taskï¼BARTï¼ã使ç¨ãã¦è©ä¾¡ããã
- ADHDã¨IGDã®åä½µçãæã¤æ£è ã¯ãåç¬ã®ADHDãæã¤æ£è ãããé«ãè¡åæ§ã示ãããã¾ãã¾ãªæ¬¡å ã§è¡¨ãã
- åå¿æå¶ãé 延å²å¼çããªã¹ãã¼ãªææ決å®è¡åãä¸æ³¨æãéæ´»åããADHDã¨IGDã®åä½µçã®ãªã¹ã¯è¦å ã¨ãã¦ç¹å®ããã
- ãããã®çµæã¯ãè¨åºç¾å ´ã«ããã¦ADHDãIGDã¨åä½µãã¦ããããæ確ã«åºå¥ããã®ã«å½¹ç«ã¤ã ãã§ãªããããæ£ç¢ºãªæ²»çã®å®æ½ã«ãå½¹ç«ã¤ã§ãããã
ã¿ã¤ãã«ï¼æ³¨ææ¬ é¥å¤åæ§é害ï¼ADHDï¼ã«ãããè³è¡æµï¼ã·ã¹ãããã£ãã¯ã¬ãã¥ã¼
è¦ç´ï¼
- èæ¯ã¨ç®ç
- ADHDã¯æãé »åº¦ãé«ããé害ãæã¤ç¥çµçºéé害ã®1ã¤ã§ãããæè¿ã®è³è¡æµï¼CBFï¼ã«é¢ããç 究ã¯ãç¥çµç²¾ç¥é害ã®åºç¤ç æ ç解ãåä¸ããã¦ããããã®ã·ã¹ãããã£ãã¯ã¬ãã¥ã¼ã¯ãADHDãæã¤äººã ã¨å¯¾ç §ç¾¤ã¨ã®éã§ã®CBFç°å¸¸ã«é¢ããæ¢åæç®ãç·åçã«ã¾ã¨ãããã¨ãç®çã¨ãã¦ããã
- æ¹æ³
- PRISMAã¢ããã¼ãã«å¾ã£ã¦ãPubMedãPsycInfoãããã³Web of
Scienceã使ç¨ãã¦ã·ã¹ãããã£ãã¯æç®æ¤ç´¢ãè¡ãããADHDã«ãããCBFã«é¢ããé¢é£ç 究ãç¹å®ãããã
- çµæ
- ADHDãæã¤1652人ã¨å¯¾ç §ç¾¤580人ã対象ã¨ãã20ã®ç 究ãå«ã¾ããSPECTï¼9ï¼ãASLï¼6ï¼ãPETï¼4ï¼ãããã³BOLDæ´¾çã®å®éçãããï¼1ï¼ããã®æ¸¬å®ãå®æ½ããããADHDã®åä½ã¯ãå®éæã«å³å´åé åéãå´é èãåºåºæ ¸ããã¿ã¡ã³ã§ä½çæµãé »ç¹ã«è¦³å¯ããããä¸æ¹ãåé èãå·¦å¾ä¸å¤®åãããã³å¾é èã§é«çæµãè¦ããããèªç¥èª²é¡ä¸ã«ã¯ãåé é åãå´é èã帯ç¶åé åãåé ç®è³ªããã³åç´°è³åã§é«çæµã観å¯ããããã¾ããã¡ãã«ãã§ããã¼ãã®æä¸ã¯ãç·æ¡ä½ã¨å¾é è³å®è³ªé¨ãå³å´è¦åºãåä¸å¿åã§CBFã®å¢å ã¨é¢é£ãã¦ããã
- çµè«
- ãã®ã¬ãã¥ã¼ã¯ãADHDã«ããããã¾ãã¾ãªCBFç°å¸¸ã強調ãã¦ãããæãä¸è²«ãã¦å ±åããã¦ããæè¦ã¯ãåé åéã¨å´é é åãããã³åºåºæ ¸ã§ã®å®éæã®ä½çæµãä¸æ¹ãåé èãé é èãããã³å¾é èã§ã®é«çæµã示åãã¦ãããADHDã«ãããCBFã®æ義ãå æ¬çã«ç解ããããã«ã¯ããããªãç 究ãç¹ã«ç¸¦æçç 究ãå¿ è¦ã§ããã
ã¿ã¤ãã«ï¼ã¤ã³ããã·ã¢ã«ããã注ææ¬ é¥å¤åæ§é害ï¼ADHDï¼ãæã¤åä¾ã®çè·ãã¿ã¼ã³ã«è¦ªã®æè²ãä¸ããå½±é¿
è¦ç´ï¼
- ADHDãæã¤åä¾ã®çè·ã«ããã親ã®æè²ã¬ãã«ã®å½±é¿ã調æ»ããããã®ç 究ã
- 70人ã®åä¾ã対象ã«ã«ã¦ã³ã»ãªã³ã°ãæ´å©ãè¡ããADHDåä¾ã®çè·ã«é¢ããä»å ¥ãå®æ½ã
- 調æ»çµæã§ã¯ã親ã®æè²ã¬ãã«ãé«ãã»ã©ADHDåä¾ãé©åãªæ²»çãåããå¾åããããã¨ã示åãããã
- çµæãããçè·ãã¿ã¼ã³ã¯è¦ªã®æè²ã¬ãã«ã«ä¾åããå¯è½æ§ããããã¨ã示åãããã
- ä»å¾ãçµæ¸ç¶æ³ã¨ç¤¾ä¼ç人å£çµ±è¨è¦å ã®ä¸ã§ADHDåä¾ã®è¦ªã®å¯¾å¦ã¹ã¿ã¤ã«ã«ãã大ããªå½±é¿ãä¸ããè¦å ãããã«ç 究ããå¿ è¦ãããã
ã¿ã¤ãã«ï¼ãã¥ã¼ãã³ã¢ã¯ã·ã§ã³ããã»ã¹ãã¬ã¼ã ã¯ã¼ã¯ãç¨ãã¦ã注ææ¬ é¥å¤åæ§é害ã®åä¾ã®ä»è·è ã«ãããè¡å決å®è¦å ã調æ»ããã
è¦ç´ï¼
- ç 究ç®çï¼HAPAçè«ãç¨ãã¦ã注ææ¬ é¥å¤åæ§é害ï¼ADHDï¼ã®åä¾ã«å¯¾ããä»è·è ã®é©å¿æ§ã¨é©åãªè²å è¡åããä»è·è ã®èæ¯ãã¡ã³ã¿ã«ãã«ã¹ã«åºã¥ãã¦è©ä¾¡ããã
- æ¹æ³ï¼24人ã®ä»è·è ãåéãã4é±ãã¨ã«èª¿æ»ãè¡ã£ããä¸ä»ããã³èª¿åå¹æã調ã¹ãããã«ã修飾ãããä¸ä»ã¢ãã«ã使ç¨ããããä»è·è ã®æå³ãè¡åãããã³ã¬ã¸ãªã¨ã³ã¹ã®å½±é¿ãæ¤è¨ããã
- çµæï¼19人ã®ä»è·è ãHAPAçè«ã®æè²ä»å ¥ãåãããã¬ã¼ãã³ã°åå¾ã®è¡åå¤åã®è©ä¾¡ãè¡ã£ãããã¬ã¼ãã³ã°å¾ãä»è·è ã®ç¥èãåä¸ããADHDã®åä¾ã¸ã®é©åãªã±ã¢æ¹æ³ã«ã¤ãã¦ã®ç¥èãåä¸ãããä»è·è ã®ã¬ã¸ãªã¨ã³ã¹ã¯è¡åå¤åã®è¦å ã¨ãªãå¯è½æ§ããããã¹ãã¬ã¹è»½æ¸ã¨ã®é¢é£ã示åããããä»è·è ãããå¼·ãããé©å¿çã§ãããã¨ã奨å±ãããã¨ã§ãã¹ãã¬ã¹è»½æ¸ã«ã¤ãªããå¯è½æ§ããããããã¯ç¹ã«ãHAPAãADHDã®åä¾ã®è²å ãã¿ã¼ã³ã«å®ç¨çãªå©ç¨ãããçè·ã«ããã¦å æ¬çãªè°è«ã¨ãªãããã
ã¿ã¤ãã«: è¥è ã®ä¸æ³¨æ/å¤åæ§ã¨ã½ã¼ã·ã£ã«ã¡ãã£ã¢ä¾åã®é¢é£ï¼èªå·±è²¬ãã¨ä»è 責ãã«ãããææ 調ç¯æ¦ç¥ã®ä¸ä»å¹æ
è¦ç´:
- ADHDã¯ãåä¾æ代ããå§ã¾ãããã°ãã°æ人æã«åã¶ä¸è¬çãªç¥çµè¡åé害ã§ãããææ 調ç¯ãè² ã®å½±é¿ãåã¼ããã½ã¼ã·ã£ã«ã¡ãã£ã¢ä¾åãªã©ã®ä¸æ¯çãªè¡åãå¼ãèµ·ããå¯è½æ§ãããã
- æ¬ç 究ã§ã¯ãè¥è ã®éã§ADHDçç¶ï¼ããªãã¡ã注ææ¬ å¦ï¼»ADï¼½ããã³å¤åæ§/è¡åæ§ï¼»HIï¼½ï¼ã¨ã½ã¼ã·ã£ã«ã¡ãã£ã¢ä¾åã®é¢é£æ§ã調æ»ããã
- èªå·±è²¬ãã¨ä»è 責ãã®å å¨åããã³å¤å¨åææ 調ç¯ï¼ããªãã¡ãSBã¨BOï¼ã®ä¸ä»å¹æãæ¤è¨¼ããã
- çµæã¯ãADHDçç¶ã¨ã½ã¼ã·ã£ã«ã¡ãã£ã¢ä¾åã®éã«ææãªæ£ã®é¢é£æ§ããããã¨ã示ããå¤ååææ 調ç¯ãADHDçç¶ã¨ã½ã¼ã·ã£ã«ã¡ãã£ã¢ä¾åã®é¢é£æ§ã仲ä»ããå¯è½æ§ããããã¨ã示åãã¦ããã
- ADãæã¤äººã¯ãèªå·±èªèï¼ãã¤ã³ããã«ãã¹ãªã©ï¼ã®åä¸ãã¬ã¸ãªã¨ã³ã¹ã¹ãã«ã®éçºãããã³è¯å®çãªã³ã¼ãã³ã°æ¦ç¥ï¼éåãªã©ï¼ã®å°å ¥ã«ç¦ç¹ãå½ã¦ããã¨ãæ¨å¥¨ãããã